Treatment for lupus is evolving. This review summarizes
|
|
- Imogen Bridges
- 6 years ago
- Views:
Transcription
1 172 Treatment of Systemic Lupus Erythematosus A 2012 Update Joan T. Merrill, M.D. Treatment for lupus is evolving. This review summarizes some of the major recommendations for care from the time of the EULAR Task Force Guidelines for SLE Treatment in 2008 through the more recent ACR guidelines for lupus nephritis which was published within the last year. Some newer papers and some reports still in abstract form are also cited, covering less conventional treatments that are available to physicians in practice. Treatments in trials which are not available to the general clinic will not be discussed here. The European League Against Rheumatism Recommendations for SLE The EULAR Task Force on SLE published guidelines for lupus treatment several years ago, which was based on an extensive literature review and expert consensus. 1 This effort was helpful in providing a framework for practical treatment decisions and in recognizing the limits to the evidence base and the many unanswered questions that remain. For this set of recommendations, the complexity of lupus was addressed efficiently, segmenting the approach to patients by whether they did or did not have major organ involvement. When a physician considers therapy for those without major organ manifestations, antimalarial or steroid treatment were recommended as well as the selective consideration of nonsteroidal antiinflammatory agents for limited periods. Of course in most lupus practices, antimalarials and steroids are not Joan T. Merrill, M.D., is in the Clinical Pharmacology Research Program at Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma. Correspondence: Joan T. Merrill, M.D., Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, 2929 NW 19th Street, Oklahoma City, Oklahoma 73107; JTMmail@aol.com. restricted to patients who are less ill. Hydroxychloroquine is usually maintained along with additional therapy when patients develop worsening disease, and the steroid doses are usually raised. For patients with more severe disease or in any patients when steroids could not be reduced to acceptable levels, immunosuppressive agents such as azathioprine, mycophenolate mofetil, and methotrexate were recommended. 1 For renal disease, cyclophosphamide (with better proof of long term efficacy) and mycophenolate mofetil (with a better side effect profile) were recommended to be given along with steroid therapy. 1 These recommendations reflected reasonable, worldwide standards of care, boiled down to a rational set of guidelines, but patients with lupus were nevertheless left with a limited set of choices between treatments which for the most part are known to have imperfect efficacy and potentially toxic consequences. Steroids: Less is More but Only if Possible Corticosteroids are the friend and the enemy to a patient with lupus. At the right individualized dose, they are rapid in onset and nearly universally effective, regardless of the organ activity that has manifested. The myriad side effects are well known, including severe toxicities and damage to the metabolic balance, cardiovascular system, eyes, bones, and (not in the least underestimated by our patients) the body habitus and general appearance. Even though all of these things are well known to physicians, the actual percentages of lupus patients who develop serious sequelae from corticosteroids can be surprising 2 and are reflective of the chronic use and difficulty in tapering these highly effective and seriously detrimental treatments. In fact, steroids are responsible for many of the most severe comorbidities that threaten patients with lupus, and may be a key factor in one of the most Merrill JT. Treatment of systemic lupus erythematosus: a 2012 update. Bull NYU Hosp Jt Dis. 2012;70(3):172-6.
2 173 common causes of complications and death for lupus patients: infection. 3,4 Is There a Science Behind Our Immune Suppressants? Azathioprine is still widely used for moderate to severe lupus in It is a pro-drug that is metabolized after ingestion to 6-mercaptopurine (the active form which is marketed as such in many parts of the world) and 6-thionosinic acid. A genetic deficiency in an enzyme which converts 6-mercaptopurine (Thiopurine S-Methyltransferase) as well as polymorphisms in genes for several other components of the same metabolic pathway can lead to hematologic and liver toxicities. 5,6 Although it has been proposed that metabolite screening be performed prior to giving azathioprine, this is not usually necessary if the dose is carefully titrated and the patient monitored with a CBC and chemistry panel with some frequency in the beginning of treatment. Mycophenolate Mofetil (MMF) (or its active form mycophenolic acid) inhibits another enzyme on the purine pathway, inosine monophosphate dehydrogenase. This mechanism can inhibit the replication of GI cells, leading to diarrhea and more significant GI disruption. 7 Like azathioprine, there are known genetic polymorphisms in this metabolic pathway that might have an impact on GI tolerance or other side effects. 8 Again, slow titration of dose at the beginning of treatment is usually sufficient to prevent major toxicity problems. These issues might limit the dosing potential for some patients for the major use of MMF in nephritis however (see below). Methotrexate is well known as an inhibitor of dihydrofolate reductase MTX, but it also acts on a number of other enzymes, leading to interference with both purine and pyrimidine pathways and DNA methylation. 9 Methotrexate is eliminated by the kidney and can become rapidly toxic, again necessitating more frequent monitoring early in the dosing period and cautious use in patients with renal impairment. 10 Leflunomide inhibits an enzyme in the pyrimidine pathway, dihydroorotate dehydrogenase. Although increasingly used when other immune suppressants fail, the evidence base for its use is not extensive. 11 Its side effect profile is similar to those of azathioprine or methotrexate, but dosing is usually per algorithm with a loading dose followed by a conventional fixed dose. Belimumab: The First Biologic Approved for Lupus Belimumab has now been available to general rheumatology practices for more than a year. The results of the Phase III trials were modest, but since there is a natural ceiling on the percentage of heterogenous lupus patients that could possibly respond to any targeted therapy, an argument can be made that the effect size was small because the trial design mandated aggressive standard of care treatments of all patients, including placebo patients. Since the approval of Belimumab, several exploratory and long-term follow up datasets have been released, showing in one exploratory analysis that the difference between placebo and belimumab was greater in subsets of what are arguably more active patients (positive anti-dsdna, low complement, treatment with mycophenolate with or without steroids, patients with renal involvement, and patients with higher SLEDAI scores) underscoring the hypothesis that this drug could be more effective than the Phase III trial design was able to demonstrate. An additional new publication provides more data on the long-term safety of this treatment over a 4 year period. 15 Unfortunately, both the United Kingdom and Germany payers have refused to cover belimumab, and this may have repercussions on access of this treatment to patients worldwide. Treatment of Nephritis In the last year, ACR guidelines specifically for the treatment of nephritis have been published. 16 Similar to the EULAR approach an extensive literature search was performed, evidence was weighted, and a panel of experts was asked to consider a number of case scenarios. Level A evidence was given to a recommendation for treatment of proliferative nephritis with steroids plus either cyclophosphamide or mycophenolate mofetil, and these regimens were considered equivalent for induction therapy, although there is better long term efficacy evidence for cyclophosphamide at this time. Mycophenolate might be the preferred treatment, however, for patients of African or Hispanic descent 16 based on some evidence that these groups respond less well to cyclophosphamide. For crescentic nephritis, the same regimen choice was recommended along with both IV pulse and high dose oral steroids. For Class V, nephritis mycophenolate and lower dose (0.5 mg/kg/day) prednisone were recommended. 16 A recent meta-analysis of studies comparing mycophenolate to cyclophosphamide in lupus nephritis suggests possible superiority of mycophenolate in overall efficacy, and when comparing side effects, there is (not surprising in either case) more diarrhea and less amenhorrea with the mycophenolate regimen. 17 However, not every study confirms this as the best induction therapy, and there is no treatment optimal for every individual. In looking at results of any treatment studies a certain degree of skepticism is always in order, since if one treatment is effective 40% of the time and another 30% of the time, it remains unclear whether that 30% includes some patients who would not have responded to the first treatment. A better connection between pathology, immune markers, and treatment selection remains elusive in When selecting a treatment for a patient with active nephritis, there are other factors to take into account as well, such as the patient s history, age, renal chronicity, tolerance of different forms of treat-
3 174 Table 1 Current Treatment Options for SLE in Clinical Practice: 2012 Treatment/Indication Not Organ Threatening Organ Threatening Nephritis Induction Nephritis Maintenance Refractory Disease Antimalarials Steroids Mycophenolate Azathioprine Methotrexate + + Leflunomide + + Cyclophosphamide + + Cyclosporine/tacrolimus + Belimumab + Rituximab/other biologics + IVIG/plasma exchange + Stem cell transplant + ment, ability to comply with an IV versus oral regimen, all of which could have a significant impact on individual efficacy. Cyclosporine A and tacrolimus have been used for nephritis for many years based on a few open label and prospective trials. These are cited as a choice for refractory patients by the ACR Guideline committee. 16 Two more small series have been published from Asia in the past year, and these treatments may provide options for individual patients when needed. 18,19 Rituximab is used for severe lupus and refractory lupus nephritis and was also cited by the ACR nephritis committee as a choice. 16 Preliminary anecdotes support the use of other biologics, including TNF inhibitors for nephritis and other severe lupus activity when alternative options are no longer possible. IVIG or plasma exchange is also used in very ill patients or those with hematologic or vascular complications, especially microangiopathy, which can occur in the context of nephritis or without renal involvement. This option was also discussed by the ACR Guideline Committee. 16 Maintenance regimens usually involve mycophenolate or, as a viable second choice, azathioprine, both of which can be effective in the right setting and prevent progressive chronic kidney disease to some extent. 20 The ACR task force cited these regimens as equivalent choices based on level A evidence. 16 Stem Cell Transplantaion This draconian measure, in which there is an attempt to rebalance a fundamentally disturbed immune system with new stem cells, is predicated on the assumption that known downstream factors which affect developing immune cells and are known to contribute to lupus may never reoccur or might at least be delayed for many years. The pioneering of SCT procedures for lupus was heralded, a decade ago, by equal degrees of adulation from the committed and horror from the skeptics. Reports of complete remission in some individuals continue to filter in. 21 However, the mortality risk coupled to continued uncertainty about the permanence of the improvement or comparative efficacy to less expensive and less dangerous therapies relegate current consideration of stem cell procedures to those patients with the most severe disease and limited alternatives. Treatment of Comorbidities Adjunctive therapies and treatment of comorbidities were not overlooked by the EULAR experts who cited healthy lifestyle modifications, such as weight control, exercise, and smoking cessation; and supplementary treatments, such as aspirin, cholesterol lowering treatment, and antihypertensives, as being important to consider. 1 It was suggested that the pros and cons of estrogen be considered and used with caution while it was acknowledged that they would be appropriate for some individuals. 1 Patients with lupus are known to be at increased risk for cardiovascular complications, 22 and the EULAR group stressed that physicians should consider the probability that these patients are at high risk. 1 Indeed, a recent report from the 30 center Systemic Lupus International Collaborating Clinics found that metabolic syndrome could already be identified in 16% of lupus patients near the time of diagnosis (mean age 35), and this was associated with a number of factors, notably and not surprisingly with steroids and renal disease. 23 Particular caution about the risk for arterial disease in the lupus population should specifically include the aggressive treatment of conventional cardiac risk factors and maintaining a high index of suspicion when events occur that could be suggestive of cardiovascular complications. Whether or not improving the control of longstanding, low-grade autoimmunity would change the long-term
4 175 prognosis for atherosclerotic complications in our patients is a compelling question which remains unknown, and must be weighed against the potential toxicities of the treatments we have at hand to achieve this. Osteoporosis is another comorbidity exacerbated by chronic use of steroid therapies that the physician can help to prevent. The EULAR recommendations include consideration of calcium and vitamin D in women who might become pregnant and bisphosphonates in postmenopausal patients. 1 Since risk for this disorder is so strongly affected by steroid therapy, there is more reason to continue doing all that is possible to minimize the use of corticosteroids. Finally, sun avoidance is an important lifestyle change that most physicians recommend, as did the EULAR guidelines, 1 but this should be counseled in the context of the impact it has on vitamin D 3, and underscores the potential importance of vitamin D supplementation. Summary and Conclusions Table 1 lists most of the treatments available to clinicians in 2012 for the treatment of lupus. In milder, non-organ threatening disease, antimalarials, lower dose steroids, and transient use of NSAIDs is usually effective. For organ threatening disease or illness that is not responding to acceptable doses of steroids, immune suppressants are initiated. Mycophenolate mofetil or cyclophosphamide are usually used as the first line treatment for nephritis, and in either case, corticosteroids are added. For maintenance therapy, either mycophenolate mofetil or azathioprine is preferred. For refractory disease, any treatments on the list might be tried and combined including biologics and antibody inhibiting strategies, such as IVIG or plasma exchange. Stem cell transplant should be reserved for the most refractory cases with the most limited options. Disclosure Statement The author has no financial or proprietary interest in the subject matter or materials discussed, including, but not limited to, employment, consultancies, stock ownership, honoraria, and paid expert testimony. References 1. Bertsias G, Ioannidis JP, Boletis J, et al. Eular Recommendations for the Management of SLE. Ann Rheum Dis Feb;67(2): Petri M. Treatment of Systemic Lupus Erythematosus: An Update. Am Fam Physician Jun;57(11): Gordon C. Long Term Complications of Systemic Lupus Erythematosus. Rheumatology (Oxford) Oct;41(10): Gladman DD, Hussain F, Ibañez D, Urowitz MB. The nature and outcome of infection in systemic lupus erythematosus. Lupus. 2002;11(4): Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther Aug; 46(2): Yamamoto K, Okada Y, Nakamura K, et al. Inosine triphosphate pyrophosphatase 94C> A polymorphism: clinical implications for patients with systemic lupus erythematosus treated with azathioprine. Expert Opin Drug Saf May;9(3): Kamar N, Faure P, Dupuis E, et al. Villous atrophy induced by mycophenolate mofetil in renal-transplant patients. Transpl Int Sep;17(8): Ohmann EL, Burckart GJ, Brooks MM, et al. Genetic polymorphisms influence mycophenolate mofetil-related adverse events in pediatric heart transplant patients. J Heart Lung Transplant May;29(5): Cutolo M, Sulli A, Pizzorni C, et al. Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann. Rheum Dis Aug;60(8): Wiela-Hojenska A, Orzechowska-Juzwenko K, Swierkot J, et al. Monitoring methotrexate therapy in patients with rheumatoid arthritis. Int J Clin Pharmacol Ther Aug;42(8): Zhang FS, Nie YK, Jin XM, et al. The efficacy and safety of leflunomide therapy in lupus nephritis by repeat kidney biopsy. Rheumatol Int Sep;29(11): Houssiau F, Dooley MA, Aranow C, D Cruz D, Askanase A, Roth DA, Cooper S, Zhong ZJ, Freimuth W, Ginzler EM, and BLISS-52/-76 Study Groups. Post hoc analysis to assess effect of belimumab in patients on mycophenolate mofetil with renal manifestations at baseline. EULAR 2011 [SAT0192]. 13. van Vollenhoven R, Schneider M, Wallace D, et al. Efficacy of belimumab in patinets with SLE: Focus on patients with low complement and positive anti-dsdna-results from BLISS 53/BLISS 76 EULAR 2011 [OP0167]. 14. Schneider M, Buyon J, Dooley MA, et al. Impact of mycophenolate mofetil and/or corticosteroid treatment on outcomes of belimumab treatment in SLE. EULAR 2012 [SAT0195]. 15. Merrill JT, Ginzler EM, Wallace DJ, et al. Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus. Arthritis Rheum Jun 5. doi: /art [Epub ahead of print]. 16. Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) Jun;64(6): Liu LL, Jiang Y, Wang LN, et al. Efficacy and safety of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: a meta-analysis of randomized controlled trials. Drugs Jul 30;72(11): Kamijo Y, Hashimoto K, Takahashi K, et al. Treatment with cyclosporine A improves SLE disease activity of Japanese patients with diffuse proliferative lupus nephritis. Clin Nephrol Aug;76(2): Yap D, YU Y, Chen X, et al. Pilot 24 month study to compare mycophenolate mofetil and tacrolimus in the treatment of membranous lupus nephritis with nephrotic syndrome. Nephrology (Carlton) May;17(4): Lenz O, Waheed AA, Baig A, et al. Lupus Nephritis: Maintenance Therapy for Lupus Nephritis--Do We Now Have a Plan? Clin J Am Soc Nephrol Aug 23. [Epub ahead of print]. 21. Mascarenhas S, Avalos B, Ardoin SP. An Update on Stem Cell
5 176 Transplantation in Autoimmune Rheumatologic Disorders. Curr Allergy Asthma Rep Sep 6. [Epub ahead of print]. 22. Manzi S, Meilahn EN, Rairie JE, et al. Age specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study. Am J Epidemiol Mar 1;145(5): Parker B, Urowitz MB, Gladman DD, et al. Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Ann Rheum Dis Sep 3. [Epub ahead of print].
Committee Approval Date: May 9, 2014 Next Review Date: May 2015
Medication Policy Manual Policy No: dru248 Topic: Benlysta, belimumab Date of Origin: May 13, 2011 Committee Approval Date: May 9, 2014 Next Review Date: May 2015 Effective Date: June 1, 2014 IMPORTANT
More informationSYSTEMIC LUPUS ERYTHEMATOSUS: CURRENT CONCEPTS AND CLINICAL PEARLS. Dr Sheila Vasoo Consultant Division of Rheumatology NUHS
SYSTEMIC LUPUS ERYTHEMATOSUS: CURRENT CONCEPTS AND CLINICAL PEARLS Dr Sheila Vasoo Consultant Division of Rheumatology NUHS Listen to the Patient Concepts Diagnosis Immunopathogenesis Clinical Pearls Disease
More informationSwitching Treatment Between Mycophenolate Mofetil and Azathioprine in Lupus Patients: Indications and Outcomes
Arthritis Care & Research Vol. 66, No. 12, December 2014, pp 1905 1909 DOI 10.1002/acr.22364 2014, American College of Rheumatology ORIGINAL ARTICLE Switching Treatment Between Mycophenolate Mofetil and
More informationLupus and Your Kidneys. Michael P. Madaio, MD Professor of Medicine Chairman of Medicine Medical College of Georgia Augusta, Georgia
Lupus and Your Kidneys Michael P. Madaio, MD Professor of Medicine Chairman of Medicine Medical College of Georgia Augusta, Georgia Kidney Inflammation and Abnormal Function as a Result of Lupus (Lupus
More informationBenlysta (belimumab) Prior Authorization Criteria Program Summary
Benlysta (belimumab) Prior Authorization Criteria Program Summary This prior authorization applies to Commercial, NetResults A series, NetResults F series and Health Insurance Marketplace formularies.
More informationEfficacy and Safety of Belimumab in the treatment of Systemic Lupus Erythematosus: a Prospective Multicenter Study.
1. Title Efficacy and Safety of Belimumab in the treatment of Systemic Lupus Erythematosus: a Prospective Multicenter Study. 2. Background Systemic Lupus Erythematosus (SLE) is a chronic, autoimmune and
More informationLupus Related Kidney Diseases. Jason Cobb MD Assistant Professor Renal Division Emory University School of Medicine October 14, 2017
Lupus Related Kidney Diseases Jason Cobb MD Assistant Professor Renal Division Emory University School of Medicine October 14, 2017 Financial Disclosures MedImmune Lupus Nephritis Kidney Biopsy Biomarkers
More informationElevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab
(2016) 25, 346 354 http://lup.sagepub.com PAPER Elevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab DA Roth 1, A Thompson 2, Y Tang 2*, AE
More informationEffect of mycophenolate mofetil on the white blood cell count and the frequency of infection in systemic lupus erythematosus.
Thomas Jefferson University Jefferson Digital Commons Department of Medicine Faculty Papers Department of Medicine 10-22-2015 Effect of mycophenolate mofetil on the white blood cell count and the frequency
More informationArthritis & Rheumatology Clinics of Kansas PATIENT EDUCATION SYSTEMIC LUPUS ERYTHEMATOSUS
Arthritis & Rheumatology Clinics of Kansas PATIENT EDUCATION SYSTEMIC LUPUS ERYTHEMATOSUS Introduction: There is perhaps no rheumatic disease that evokes so much fear and confusion among both patients
More informationUnderstanding Myositis Medications
Understanding Myositis Medications 2015 TMA Annual Patient Conference Orlando, Florida Chester V. Oddis, MD University of Pittsburgh Director, Myositis Center Disclosures Mallinckrodt: Research Grant Genentech:
More informationLupus nephritis. Vladimir Tesar Department of Nephrology, General University Hospital, Prague, Czech Republic
Lupus nephritis Vladimir Tesar Department of Nephrology, General University Hospital, Prague, Czech Republic Disclosure of Interests Abbvie, Amgen, Baxter, Bayer, Boehringer-Ingelheim, Calliditas, Chemocentryx,
More informationONE of the following:
Medical Coverage Policy Belimumab (Benlysta) EFFECTIVE DATE: 01 01 2012 POLICY LAST UPDATED: 11 21 2017 OVERVIEW Belimumab (Benlysta ) is indicated for the treatment of adult patients with active, autoantibody-positive,
More informationLupus. Fast facts. What is lupus? What causes lupus? Who gets lupus?
Lupus Systemic lupus erythematosus, referred to as SLE or lupus, is sometimes called the "great imitator." Why? Because of its wide range of symptoms, people often confuse lupus with other health problems.
More informationAdditional file 2: Details of cohort studies and randomised trials
Reference Randomised trials Ye et al. 2001 Abstract 274 R=1 WD=0 Design, numbers, treatments, duration Randomised open comparison of: (45 patients) 1.5 g for 3, 1 g for 3, then 0.5 to 0.75 g IV cyclophosphamide
More informationLONG-TERM OUTCOME OF PATIENTS WITH LUPUS NEPHRITIS: A SINGLE CENTER EXPERIENCE
& LONG-TERM OUTCOME OF PATIENTS WITH LUPUS NEPHRITIS: A SINGLE CENTER EXPERIENCE Senija Rašić 1 *, Amira Srna 1, Snežana Unčanin 1, Jasminka Džemidžić 1, Damir Rebić 1, Alma Muslimović 1, Maida Rakanović-Todić
More informationTaming the wolf: Treating to target, treating to remission new strategies for SLE
Taming the wolf: Treating to target, treating to remission new strategies for SLE Ronald van Vollenhoven Seattle, April 28, 2017 Disclosures Research support, consultancy: Abbott (AbbVie), Biotest, BMS,
More informationBenlysta. Benlysta (belimumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.99.01 Subject: Benlysta Page: 1 of 5 Last Review Date: June 22, 2018 Benlysta Description Benlysta (belimumab)
More informationMEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 08/19/14 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:
RITUXAN (rituximab) Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Medical Coverage Guideline
More informationLupus Nephritis New (?) Treatments. Aurélie HUMMEL Service de Néphrologie Hôpital Necker Enfants-Malades Paris
Lupus Nephritis New (?) Treatments Aurélie HUMMEL Service de Néphrologie Hôpital Necker Enfants-Malades Paris Introduction Lupus nephritis : 30-50% of patients with lupus = mortality risk factor Mok Series
More informationMandana Nikpour 1,2, Murray B Urowitz 1*, Dominique Ibanez 1, Paula J Harvey 3 and Dafna D Gladman 1. Abstract
RESEARCH ARTICLE Open Access Importance of cumulative exposure to elevated cholesterol and blood pressure in development of atherosclerotic coronary artery disease in systemic lupus erythematosus: a prospective
More informationBenlysta. Benlysta (belimumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Benlysta Page: 1 of 5 Last Review Date: December 3, 2015 Benlysta Description Benlysta (belimumab)
More information47 studies found for: systemic lupus erythematosus AND mycophenolic acid
Recherche in auf der Webseite www.clinicaltrials.gov zuletzt am 16.02.2016 47 studies found for: systemic lupus erythematosus AND mycophenolic acid Rank Status Study 1 Terminate d Myfortic Versus Azathioprine
More informationIf It s Not One Thing It s Another: Transformation of Lupus Nephritis
HALLWAY CONSULT If It s Not One Thing It s Another: Transformation of Lupus Nephritis By Julie Barsalou, MD, FRCPC; Rohan John, MD; and Joanne M. Bargman, MD, FRCPC A 25-year-old Haitian-born woman presents
More informationRonald F. van Vollenhoven Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID) The Karolinska Institute Stockholm, Sweden
Ronald F. van Vollenhoven Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID) The Karolinska Institute Stockholm, Sweden Disclosures Research Grants: AbbVie, Amgen, BMS, GSK, Pfizer, Roche,
More informationLupus and the heart. Lupus Foundation of America
Lupus and the heart Lupus Foundation of America Teleconference FEB 2015 Premature Atherosclerotic ti Cardiovascular Disease in Systemic Lupus Erythematosus Joan M. Von Feldt, MD, MSEd Professor of Medicine
More informationREMISSION OF ACTIVE LUPUS NEPHRITIS WITH VOCLOSPORIN: RESULTS OF THE AURA-LV STUDY
REMISSION OF ACTIVE LUPUS NEPHRITIS WITH VOCLOSPORIN: RESULTS OF THE AURA-LV STUDY V. Dobronravov* 1, M. A. Dooley 2, S. A. Haq 3, I. Adzerikho 4, O. Bugrova 5, D. Isenberg 6, F. Houssiau 7, N. Solomons
More information* Autoantibody positive (i.e. antinuclear antibody or ANA titre 1:80 or anti-double stranded (ds) DNA antibody 30 IU/mL)
Benlysta (belimumab) Policy Number: 5.02.509 Last Review: 05/2018 Origination: 06/2011 Next Review: 05/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Benlysta
More informationClinical Commissioning Policy Statement: Rituximab For Systemic Lupus Erythematosus (SLE) December Reference : NHSCB/A3C/1b
Clinical Commissioning Policy Statement: Rituximab For Systemic Lupus Erythematosus (SLE) December 2012 Reference : NHSCB/A3C/1b NHS Commissioning Board Clinical Commissioning Policy Statement: Rituximab
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC Update on the Treatment of Rheumatoid Arthritis Sabrina Fallavollita MDCM McGill University Canadian Society of Internal Medicine
More informationEvidence Based Treatment of SLE with Treatment Algorithm. Dr. Md. Mujibur Rahman Professor of Medicine Shaheed Suhrawardy Medical College
Evidence Based Treatment of SLE with Treatment Algorithm Dr. Md. Mujibur Rahman Professor of Medicine Shaheed Suhrawardy Medical College Natural Histoty Inflammatory multisystem disease Onset usually between
More informationCorporate Presentation January 2013
NASDAQ: ANTH Corporate Presentation January 2013 1 Forward Looking Statements This presentation contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationLUPUS. and Medication LUPUSUK 2015
9 LUPUS and Medication LUPUSUK 2015 LUPUS and Medication The types of drugs used in lupus can be broadly divided into those that treat the disease itself (e.g. hydroxychloroquine and prednisolone) and
More informationLearning about Lupus. Learning About Lupus. Lupus Society of Illinois
Learning About Lupus Learning about Lupus Lupus Society of Illinois 525 W. Monroe Street, Suite 900 Chicago, Illinois 60661 Robert S. Katz, M.D. Professor of Medicine Rush University Medical Center Northwestern
More informationEXTENDED REPORT. Clinical and epidemiological research
1 Allegheny Singer Research Institute, West Penn Allegheny Health System, Temple University School of Medicine, Pittsburgh, Pennsylvania, USA 2 Instituto Nacional de Ciencias Medicas y Nutricion Salvador
More informationHorizon Scanning Centre May Tabalumab for systemic lupus erythematosus SUMMARY NIHR HSC ID: 5581
Horizon Scanning Centre May 2014 Tabalumab for systemic lupus erythematosus SUMMARY NIHR HSC ID: 5581 This briefing is based on information available at the time of research and a limited literature search.
More informationTHE KIDNEY AND SLE LUPUS NEPHRITIS
THE KIDNEY AND SLE LUPUS NEPHRITIS JACK WATERMAN DO FACOI 2013 NEPHROLOGY SIR RICHARD BRIGHT TERMINOLOGY RENAL INSUFFICIENCY CKD (CHRONIC KIDNEY DISEASE) ESRD (ENDSTAGE RENAL DISEASE) GLOMERULONEPHRITIS
More informationIntravenous cyclophosphamide combined with steroids in pediatric onset severe lupus nephritis
Int Urol Nephrol (2013) 45:1301 1308 DOI 10.1007/s11255-012-0331-9 NEPHROLOGY - ORIGINAL PAPER Intravenous cyclophosphamide combined with steroids in pediatric onset severe lupus nephritis Prayong Vachvanichsanong
More informationNew Evidence reports on presentations given at EULAR Rituximab for the Treatment of Rheumatoid Arthritis and Vasculitis
New Evidence reports on presentations given at EULAR 2011 Rituximab for the Treatment of Rheumatoid Arthritis and Vasculitis Report on EULAR 2011 presentations Anti-TNF failure and response to rituximab
More informationBaseline Predictors of Systemic Lupus Erythematosus Flares
ARTHRITIS & RHEUMATISM Vol. 65, No. 8, August 2013, pp 2143 2153 DOI 10.1002/art.37995 2013, American College of Rheumatology Baseline Predictors of Systemic Lupus Erythematosus Flares Data From the Combined
More informationBelimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response
ARD Online First, published on April 5, 2012 as 10.1136/annrheumdis-2011-200937 1 Unit for Clinical Therapy Research, Infl ammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden 2 Division
More informationErythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE
To cite: Merrill JT, Petri MA, Buyon J, et al. Erythrocytebound C4d in combination with complement and autoantibody status for the monitoring of SLE. Lupus Science & Medicine 2018;5:e000263. doi:10.1136/
More informationTreat-to-target in lupus: what does the future hold?
International Journal of Clinical Rheumatology Treat-to-target in lupus: what does the future hold? Implementing a treat-to-target (T2T) strategy that aims to improve disease outcomes through achievement
More information10/25/2018. Autoimmunity and how to treat it. Disclosure. Why do we get autoimmunity? James Verbsky MD/PhD Pediatric Rheumatology/Immunology
Autoimmunity and how to treat it James Verbsky MD/PhD Pediatric Rheumatology/Immunology Disclosure None I will mention drug names and some brand names but I have no financial interest or any other ties
More information4/16/2018. Demystifying weakness: how to approach refractory myositis. Objectives. Disclosures. Off-label uses for medications will be discussed
Demystifying weakness: how to approach refractory myositis Jemima Albayda, MD Assistant Professor Johns Hopkins Myositis center Disclosures Off-label uses for medications will be discussed Objectives To
More informationUNFOLDING NATURE S ORIGAMI: MEDICAL TREATMENT OF TAKAYASU ARTERITIS AND GIANT CELL ARTERITIS
UNFOLDING NATURE S ORIGAMI: MEDICAL TREATMENT OF TAKAYASU ARTERITIS AND GIANT CELL ARTERITIS CanVasc meeting Montreal Nov 22 2012 Patrick Liang Service de rhumatologie Centre Hospitalier Universitaire
More informationLONGITUDINAL TREATMENT PATTERNS AND ASSOCIATED OUTCOMES IN PATIENTS WITH NEWLY DIAGNOSED SYSTEMIC LUPUS ERYTHEMATOSUS. Hong Kan 7/12/2016
LONGITUDINAL TREATMENT PATTERNS AND ASSOCIATED OUTCOMES IN PATIENTS WITH NEWLY DIAGNOSED SYSTEMIC LUPUS ERYTHEMATOSUS Hong Kan 7/12/2016 1 Acknowledgements Research conceptualization and design, programming
More informationMEDICAL POLICY. Proprietary Information of YourCare Health Plan
MEDICAL POLICY Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature generally recognized by the medical community.
More informationTHE CARDIOVASCULAR INFLAMMATORY CONTINUUM DR AB MAHARAJ
THE CARDIOVASCULAR INFLAMMATORY CONTINUUM DR AB MAHARAJ Disclosures: On National Advisory Boards of: (1) Pfizer Pharmaceuticals (2) MSD (3) Roche Pharmaceuticals (4) Abbott International: AfME Rheumatology
More information29/10. Treatment (brand name, manufacturer): For the treatment of: Background: Rituximab (MabThera, Roche) SLE in adults (unlicensed)
GENERAL POLICY Policy Ref: 29/10 Treatment (brand name, manufacturer): For the treatment of: Background: Commissioning position: Rituximab (MabThera, Roche) SLE in adults (unlicensed) There are frequent
More informationCoverage Criteria: Express Scripts, Inc. monograph dated 12/15/ months or as otherwise noted by indication
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Kineret (anakinra subcutaneous injection) Commercial HMO/PPO/CDHP
More informationNeuropsychiatric Systemic Lupus Erythematosus (NPSLE) Case presentations and topic discussion The Rheumatology Unit UMMC experience
Neuropsychiatric Systemic Lupus Erythematosus (NPSLE) Case presentations and topic discussion The Rheumatology Unit UMMC experience References Sanna G, Bertolaccini ML. Neuropsychiatric manifestations
More informationCase Presentation. A Case from the Clinic. Additional Data. Examination and Data 10/27/2013
Northwestern University Feinberg School of Medicine Treatment of Severe Thrombocytopenia in Systemic Lupus Erythematosus: The Role of New Agents Disclosures: Advisory Board: Incyte Corporation Speaker
More informationRecent advances in management of Pulmonary Vasculitis. Dr Nita MB
Recent advances in management of Pulmonary Vasculitis Dr Nita MB 23-01-2015 Overview of the seminar Recent classification of Vasculitis What is new in present classification? Trials on remission induction
More informationLife Science Journal 2015;12(3s) Study on the effect of Mycophenolate Mofetil in lupus nephritis treatment
Study on the effect of Mycophenolate Mofetil in lupus nephritis treatment Mohammad Reza Jafari Nakhjavani 1, Sima Abedi Azar 2* 1. Assistant Professor of Rheumatology, Connective Tissue Diseases Research
More informationIMPACT OF LONG TERM-STEROID TREATMENT PRESCRIBED FOR SYSTEMIC AND AUTOIMMUNE DISEASES ON THE DEVELOPMENT OF ATHEROSCLEROSIS.
1 IMPACT OF LONG TERM-STEROID TREATMENT PRESCRIBED FOR SYSTEMIC AND AUTOIMMUNE DISEASES ON THE DEVELOPMENT OF ATHEROSCLEROSIS. A NETWORK ORGANIZED BY THE EUROPEAN FEDERATION OF INTERNAL MEDICINE Coordination:
More informationLupus The Clinical Perspective
Lupus The Clinical Perspective Anca D. Askanase, M.D., M.P.H. Associate Professor of Medicine Director Lupus Center Columbia University Medical Center New York-Presbyterian Hospital Systemic Lupus Erythematosus
More informationDisclosures. Evidence Based Medicine. Infections in SLE and LN Patients. Aim
Serious Infection Rates among Patients with Systemic Lupus Erythematosus Receiving Corticosteroids and Immunosuppressants None Disclosures Candace H. Feldman, MD, MPH 1,2 Linda T. Hiraki, MD, SM, ScD 3
More informationNephrotic syndrome minimal change disease vs. IgA nephropathy. Hadar Meringer Internal medicine B Sheba
Nephrotic syndrome minimal change disease vs. IgA nephropathy Hadar Meringer Internal medicine B Sheba The Case 29 year old man diagnosed with nephrotic syndrome 2 weeks ago and complaining now about Lt.flank
More informationEfficacy and Safety of Rituximab in the Treatment of Rheumatoid Arthritis and ANCA-associated Vasculitis
New Evidence reports on presentations given at ACR/ARHP 2010 Efficacy and Safety of Rituximab in the Treatment of Rheumatoid Arthritis and ANCA-associated Vasculitis Report on ACR/ARHP 2010 presentations
More informationPDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Wed, 20 Jun 2018 01:15:28 GMT) CTRI Number Last Modified On 29/12/2012 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study
More informationDevelopment of SLE among Possible SLE Patients Seen in Consultation: Long-Term Follow-Up. Disclosures. Background. Evidence-Based Medicine.
Development of SLE among Patients Seen in Consultation: Long-Term Follow-Up Abstract # 1699 May Al Daabil, MD Bonnie L. Bermas, MD Alexander Fine Hsun Tsao Patricia Ho Joseph F. Merola, MD Peter H. Schur,
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: belimumab_benlysta 6/2011 2/2018 2/2019 3/2018 Description of Procedure or Service Belimumab (Benlysta) is
More informationImmunosuppressants. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Immunosuppressants Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Immunosuppressive Agents Very useful in minimizing the occurrence of exaggerated or inappropriate
More informationRenal Flare as a Predictor of Incident and Progressive CKD in Patients with Lupus Nephritis
Article Renal Flare as a Predictor of Incident and Progressive in Patients with Lupus Nephritis Samir V. Parikh,* Haikady N. Nagaraja, Lee Hebert,* and Brad H. Rovin* Summary Background and objectives
More informationTechnology appraisal guidance Published: 22 June 2016 nice.org.uk/guidance/ta397
Belimumab for treating active autoantibody-positive systemic lupus erythematosus Technology appraisal guidance Published: 22 June 2016 nice.org.uk/guidance/ta397 NICE 2018. All rights reserved. Subject
More informationAurinia Pharmaceuticals Announces Voclosporin Meets Primary Endpoint in Phase IIB AURA-LV Study in Lupus Nephritis
August 15, 2016 Aurinia Pharmaceuticals Announces Voclosporin Meets Primary Endpoint in Phase IIB AURA-LV Study in Lupus Nephritis Conference call and webcast at 8am ET First therapeutic agent to meet
More informationNew Drug Evaluation: Belimumab Injection, Intravenous and Subcutaneous
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationLupus as a risk factor for cardiovascular disease
Lupus as a risk factor for cardiovascular disease SØREN JACOBSEN Department Rheumatology, Rigshospitalet Søren Jacobsen Main sponsors: Gigtforeningen Novo Nordisk Fonden Rigshospitalet Disclaimer: Novo
More informationSystemic Lupus Erythematosus (SLE) Epidemiology of SLE (United States)
1:10-2:25pm Closing the Loop on Lupus: Primary Care s Key Role in the Elusive Diagnosis and Management of Patients SPEAKER Richard Sadovsky, MD Richard Furie, MD Disclosures This session is supported by
More informationBK Virus (BKV) Management Guideline: July 2017
BK Virus (BKV) Management Guideline: July 2017 BK virus has up to a 60-80% seroprevalence rate in adults due to a primary oral or respiratory exposure in childhood. In the immumocompromised renal transplant
More informationENFERMEDADES AUTOINMUNES SISTÉMICAS. Dr. J. María Pego Reigosa
ENFERMEDADES AUTOINMUNES SISTÉMICAS Dr. J. María Pego Reigosa ABSTRACT NUMBER: 888 PHASE 3 TRIAL RESULTS WITH BLISIBIMOD, A SELECTIVE INHIBITOR OF B-CELL ACTIVATING FACTOR, IN SUBJECTS WITH MODERATE-TO-SEVERE
More informationIdentification of clinical and serological factors during induction treatment of lupus nephritis that are associated with renal outcome
To cite: Dall Era M, Levesque V, Solomons N, et al. Identification of clinical and serological factors during induction treatment of lupus nephritis that are associated with renal outcome. Lupus Science
More informationMEDICAL POLICY SUBJECT: GENOTYPING OR PHENOTYPING FOR THIOPURINE METHYLTRANSFERASE (TPMT) FOR PATIENTS TREATED WITH AZATHIOPRINE (6-MP)
MEDICAL POLICY SUBJECT: GENOTYPING OR PHENOTYPING PAGE: 1 OF: 5 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product (including
More informationTo live with lupus, we need to know about lupus.
To live with lupus, we need to know about lupus. Zineb Aouhab, MD Assistant Professor of Medicine Loyola University Medical Center Division of Rheumatology 1 Where did the word lupus come from? The word
More informationTable S1. Read and ICD 10 diagnosis codes for polymyalgia rheumatica and giant cell arteritis
SUPPLEMENTARY MATERIAL TEXT Text S1. Multiple imputation TABLES Table S1. Read and ICD 10 diagnosis codes for polymyalgia rheumatica and giant cell arteritis Table S2. List of drugs included as immunosuppressant
More informationEffective Health Care Program
Comparative Effectiveness Review Number 28 Effective Health Care Program Disease-Modifying Antirheumatic Drugs (DMARDs) in Children With Juvenile Idiopathic Arthritis (JIA) Executive Summary Background
More informationIRACON Management of Lupus Nephritis: Old is gold, New is Trendy
IRACON 2016 Management of Lupus Nephritis: Old is gold, New is Trendy First episode of LN (III/IV): Induction Low dose is equally considerable as high dose CYC Switch to the other agent if no improvement
More informationRheumatology Suggested Reading List. Compiled by Rebecca Sharim MD. Updated: 4/6/17
Rheumatology Suggested Reading List Compiled by Rebecca Sharim MD Updated: 4/6/17 Rheumatoid Arthritis: 1994: Elliott, Michael J., et al. "Randomised double-blind comparison of chimeric monoclonal antibody
More informationLiving with Lupus. Helping Your Patient With Systemic Lupus Erythematosus By Hussein M. Halaby, MBBS, ABIM, FRCPC; and John M. Esdaile, MD, MPH, FRCPC
Focus on CME at the University McGill University of British Columbia Living with Lupus Helping Your Patient With Systemic Lupus Erythematosus By Hussein M. Halaby, MBBS, ABIM, FRCPC; and John M. Esdaile,
More informationBelimumab for Systemic Lupus Erythematosus
T h e n e w e ngl a nd j o u r na l o f m e dic i n e clinical therapeutics Belimumab for Systemic Lupus Erythematosus Bevra Hannahs Hahn, M.D. This Journal feature begins with a case vignette that includes
More informationMarket Access CTR Summary
Market Access CTR Summary Study No.: BEL114246 Title: Efficacy of Belimumab Treatment in a Subpopulation of Systemic Lupus Erythematosus (SLE) Patients: A Pooled Analysis of the HGS1006-C1056 (BLISS-52)
More informationAmerican College of Rheumatology
SPECIAL REPORT Highlights from the American College of Rheumatology Meeting Chicago, IL 2011 > Highlights of the American College of Rheumatology 2011 Annual Scientific Meeting > First Lupus Nephritis
More informationIroko Pharmaceuticals Receives FDA Approval for VIVLODEX - First Low Dose SoluMatrix Meloxicam for Osteoarthritis Pain
Iroko Pharmaceuticals Receives FDA Approval for VIVLODEX - First Low Dose SoluMatrix Meloxicam for Osteoarthritis Pain VIVLODEX Developed to Align with FDA NSAID Recommendations Proven Efficacy at Low
More informationChapter 4: Steroid-resistant nephrotic syndrome in children Kidney International Supplements (2012) 2, ; doi: /kisup.2012.
http://www.kidney-international.org & 2012 KDIGO Chapter 4: Steroid-resistant nephrotic syndrome in children Kidney International Supplements (2012) 2, 172 176; doi:10.1038/kisup.2012.17 INTRODUCTION This
More informationCorrelation between Systemic Lupus Erythematosus Disease Activity Index, C3, C4 and Anti-dsDNA Antibodies
Original Article Correlation between Systemic Lupus Erythematosus Disease Activity Index, C3, C4 and Anti-dsDNA Antibodies Col K Narayanan *, Col V Marwaha +, Col K Shanmuganandan #, Gp Capt S Shankar
More informationPersistent disease activity may have significant implications for your SLE patients life journey. 1,2
Persistent disease activity may have significant implications for your SLE patients life journey. 1,2 Is it time to increase the focus on disease activity reduction? BENLYSTA (belimumab) is indicated as
More informationSituaciones estresantes en el lupus
Situaciones estresantes en el lupus Munther A Khamashta MD FRCP PhD Director: Lupus Research Unit Barcelona, Noviembre 2008 What is Lupus? Lupus is a neurological disease and sometimes affects other organs
More informationACP Rheumatology Pearls. Adam Q Carlson MD Assistant Professor UVA Rheumatology
ACP Rheumatology Pearls Adam Q Carlson MD Assistant Professor UVA Rheumatology Disclosures I have no personal or professional disclosures Case #1 27 yo woman with a history of systemic lupus complicated
More informationBelimumab for the treatment of autoantibody-active systemic lupus erythematosus
National Institute for Health and Clinical Excellence Comment 1: the draft remit Single Technology Appraisal (STA) Belimumab for the treatment of autoantibody-active systemic lupus erythematosus Response
More informationWhich outcome measures in SLE clinical trials best reflect medical judgment?
To cite: Thanou A, Chakravarty E, James JA, et al. Which outcome measures in SLE clinical trials best reflect medical judgment? Lupus Science & Medicine 2014;1:e000005. doi:10.1136/lupus-2013-000005 Received
More informationEULAR/ERA-EDTA recommendations for the management of ANCAassociated
EULAR/ERA-EDTA recommendations for the management of ANCAassociated vasculitis Dr. Meharunnisha Syed III year DNB Resident (General Medicine) Narayana Health-MSH Fifteen recommendations were developed,
More information9/25/2013 SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) 1 Other Types of Lupus Discoid Lupus Erythematosus Lupus Pernio --- Sarcoidosis Lupus Vulgaris --- Tuberculosis of the face Manifestations of SLE Fever Rashes Arthritis
More informationLUPUS CAN DO EVERYTHING, BUT NOT EVERYTHING IS LUPUS LUPUS 101 SLE SUBSETS AUTOIMMUNE DISEASE 11/4/2013 HOWARD HAUPTMAN, MD IDIOPATHIC DISCOID LUPUS
LUPUS 101 LUPUS CAN DO EVERYTHING, BUT NOT EVERYTHING IS LUPUS HOWARD HAUPTMAN, MD IDIOPATHIC DISCOID LUPUS SLE SUBSETS SUBACUTE CUTANEOUS LUPUS DRUG INDUCED LUPUS NEONATAL LUPUS LATE ONSET LUPUS ANTI-PHOSPHOLIPID
More informationLupus. and the Kidneys
Lupus and the Kidneys LupusuK 2015 This information booklet has been produced by LUPUS UK 2015 LUPUS UK LUPUS UK is the national charity caring for those with systemic lupus erythematosus (SLE) and discoid
More informationSpondyloarthropathies: Disease Perception Limits Market
Spondyloarthropathies: Disease Perception Limits Market Psoriatic arthritis and ankylosing spondylitis form part of the group of diseases known as the spondyloarthropathies. Psoriatic arthritis is a form
More informationAccepted Article. Comparative Fracture Risks among US Medicaid Enrollees with and without Systemic. Lupus Erythematosus
DR. SEOYOUNG C. KIM (Orcid ID : 0000-0002-2517-3579) Article type : Brief Report Comparative Fracture Risks among US Medicaid Enrollees with and without Systemic Lupus Erythematosus Sara K. Tedeschi, MD,
More informationSevere lupus nephritis: the predictive value of a 50% reduction in proteinuria at 6 months
Nephrol Dial Transplant (2013) 28: 2313 2318 doi: 10.1093/ndt/gft201 Advance Access publication 19 June 2013 Severe lupus nephritis: the predictive value of a 50% reduction in proteinuria at 6 months Stephen
More informationCooper et al. Pediatric Rheumatology (2018) 16:65 (Continued on next page)
Cooper et al. Pediatric Rheumatology (2018) 16:65 https://doi.org/10.1186/s12969-018-0279-0 RESEARCH ARTICLE Pilot study comparing the childhood arthritis and rheumatology research alliance consensus treatment
More informationKidney disease associated with autoimmune disease
Kidney disease associated with autoimmune disease Masaomi Nangaku Division of Nephrology and Endocrinology the University of Tokyo Graduate School of Medicine, Japan M-type Phospholipase A2 Receptor as
More information